Concepedia

Kenneth Todd Moore

KT

Statistics

Publications

21

Citations

1.1K

H-Index

16

Active since

1993

Affiliations

Janssen (United States)(Current)

Janssen Scientific Affairs (United States)

Johnson & Johnson (United States)

University of Connecticut

Janssen (Belgium)

Kenneth Todd Moore is an author at Janssen (United States) specializing in pharmacology, clinical pharmacology, and anticoagulant therapy.

ORCID

Publications per year

1993–2022

21

Publications

21

Comparison of three‐factor and four‐factor prothrombin complex concentrates regarding reversal of the anticoagulant effects of rivaroxaban in healthy volunteers

Marcel Levi, Kenneth Todd Moore, C.F. Castillejos et al. · Journal of Thrombosis and Haemostasis · 2014 · 193 citations

, , +13

Pharmacokinetics, Pharmacodynamics, and Safety of Single-Dose Rivaroxaban in Chronic Hemodialysis

Clapton Dias, Kenneth Todd Moore, Joe Murphy et al. · American Journal of Nephrology · 2016 · 130 citations · Full text

, , +17

Population pharmacokinetics and pharmacodynamics of rivaroxaban in patients with non‐valvular atrial fibrillation: Results from ROCKET AF

Ihab Girgis, Manesh R. Patel, Gary Peters et al. · The Journal of Clinical Pharmacology · 2014 · 109 citations

, , +16

Expression of the human neuropeptide tyrosine Y1 receptor.

John Wharton, L Gordon, Johanna Byrne et al. · Proceedings of the National Academy of Sciences · 1993 · 90 citations

, , +17

Rivaroxaban versus warfarin in patients with nonvalvular atrial fibrillation and stage IV-V chronic kidney disease

Veronica Ashton, Kenneth Todd Moore, Shubham Shrivastava et al. · American Heart Journal · 2020 · 63 citations · Full text

, , +17

1–5 of 21